Stuart Snyder

Array ( [id] => 12145038 [patent_doc_number] => 09879281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Recombinant vaccinia virus derived from KVAC103 strain' [patent_app_type] => utility [patent_app_number] => 14/883752 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 6644 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14883752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992497 [patent_doc_number] => 20170296650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'COMBINATION OF HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/516655 [patent_app_country] => US [patent_app_date] => 2015-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 32877 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10728358 [patent_doc_number] => 20160074507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 14/855744 [patent_app_country] => US [patent_app_date] => 2015-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 23425 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14855744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13011811 [patent_doc_number] => 10029006 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Vaccine against bovine leukemia virus [patent_app_type] => utility [patent_app_number] => 14/832863 [patent_app_country] => US [patent_app_date] => 2015-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 18 [patent_no_of_words] => 29619 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14832863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678044 [patent_doc_number] => 20160024188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/817707 [patent_app_country] => US [patent_app_date] => 2015-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 34850 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14817707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10687387 [patent_doc_number] => 20160033532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'MAMMALIAN PROTEIN CO-RECOGNITION BY BROADLY NEUTRALIZING ANTIBODIES AS MODIFIED IMMUNOGENS FOR RE-ELICITATION' [patent_app_type] => utility [patent_app_number] => 14/813519 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14889 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14813519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821849 [patent_doc_number] => 20170210786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'Combination of Broadly Neutralizing HIV Antibodies and Viral Inducers' [patent_app_type] => utility [patent_app_number] => 15/327725 [patent_app_country] => US [patent_app_date] => 2015-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 16840 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10428978 [patent_doc_number] => 20150313989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'Immunogenic Influenza Composition' [patent_app_type] => utility [patent_app_number] => 14/801770 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14120 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14801770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11742882 [patent_doc_number] => 20170196954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR' [patent_app_type] => utility [patent_app_number] => 15/326052 [patent_app_country] => US [patent_app_date] => 2015-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 49703 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422553 [patent_doc_number] => 10316066 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection [patent_app_type] => utility [patent_app_number] => 15/320033 [patent_app_country] => US [patent_app_date] => 2015-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 25 [patent_no_of_words] => 12968 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15320033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13065793 [patent_doc_number] => 10053671 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Mutations that confer genetic stability to additional genes in influenza viruses [patent_app_type] => utility [patent_app_number] => 14/745236 [patent_app_country] => US [patent_app_date] => 2015-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 49 [patent_no_of_words] => 28009 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14745236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14143191 [patent_doc_number] => 10251947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Influenza vaccines [patent_app_type] => utility [patent_app_number] => 14/744924 [patent_app_country] => US [patent_app_date] => 2015-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 29 [patent_no_of_words] => 26573 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14744924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14391335 [patent_doc_number] => 10308938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Compositions and methods to activate or inhibit toll-like receptor signaling [patent_app_type] => utility [patent_app_number] => 15/319132 [patent_app_country] => US [patent_app_date] => 2015-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 85 [patent_no_of_words] => 14879 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15319132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11590010 [patent_doc_number] => 20170114420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'APTAMERS WITH BINDING AFFINITY TO NOROVIRUS' [patent_app_type] => utility [patent_app_number] => 15/317002 [patent_app_country] => US [patent_app_date] => 2015-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 47480 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15317002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10461198 [patent_doc_number] => 20150346213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'PLASMA CYTOCHROME C AS A BIOMARKER FOR MITOCHONDRIAL TOXICITY DURING ANTIRETROVIRAL THERAPY' [patent_app_type] => utility [patent_app_number] => 14/725835 [patent_app_country] => US [patent_app_date] => 2015-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9762 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14725835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11698840 [patent_doc_number] => 09688744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'High affinity human antibodies to human cytomegalovirus (CMV) GB protein' [patent_app_type] => utility [patent_app_number] => 14/697459 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7163 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14697459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11699061 [patent_doc_number] => 09688965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Recombinant neuraminidase and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/685286 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 46 [patent_no_of_words] => 4810 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14685286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318922 [patent_doc_number] => 20150203925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'LIQUID CRYSTAL BASED ANALYTE DETECTION' [patent_app_type] => utility [patent_app_number] => 14/663000 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 40007 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14663000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11262238 [patent_doc_number] => 09486518 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine' [patent_app_type] => utility [patent_app_number] => 14/642233 [patent_app_country] => US [patent_app_date] => 2015-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 26703 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14642233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678010 [patent_doc_number] => 20160024156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'ANTIVIRAL VACCINES WITH IMPROVED CELLULAR IMMUNOGENICITY' [patent_app_type] => utility [patent_app_number] => 14/632869 [patent_app_country] => US [patent_app_date] => 2015-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 18361 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14632869 [rel_patent_id] =>[rel_patent_doc_number] =>)